Status:
COMPLETED
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Lead Sponsor:
UCB Pharma
Conditions:
Dyskinesia, Medication-induced
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
Eligibility Criteria
Inclusion
- Subjects between ages 18 and 80 years
- Subjects must have a diagnosis of stable axis I psychiatric disorder at least 6 months prior to screening
- Subjects must have a stable neuroleptic-induced tardive dyskinesia at least 1 month prior to screening and meet tardive dyskinesia severity criteria
- Subjects must have used antipsychotics for at least 6 cumulative months, and, be on a stable dose for 1 month prior to screening
Exclusion
- Presence of any axis II condition within 6 months prior to screening
- Huntington´s disease, idiopathic dystonia, Wilson´s disease, Sydenham´s chorea, thyroid dysfunction, spontaneous dyskinesia
- Start of drugs-other than neuroleptics- that can cause dyskinesia
- Presence of additional major disease such as cardiac, renal or hepatic dysfunction or terminal illness
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00175955
Start Date
May 1 2005
End Date
December 1 2005
Last Update
December 6 2013
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Antwerp, Belgium
2
Bourgois, Belgium
3
Gonce, Belgium
4
Hulselmans, Belgium